State of Wisconsin Investment Board Buys Shares of 485,600 NxStage Medical, Inc. (NXTM)

State of Wisconsin Investment Board bought a new position in NxStage Medical, Inc. (NASDAQ:NXTM) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 485,600 shares of the medical device company’s stock, valued at approximately $13,403,000. State of Wisconsin Investment Board owned approximately 0.73% of NxStage Medical at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of the company. Suntrust Banks Inc. raised its holdings in shares of NxStage Medical by 2.3% in the 2nd quarter. Suntrust Banks Inc. now owns 9,480 shares of the medical device company’s stock worth $237,000 after buying an additional 209 shares in the last quarter. Principal Financial Group Inc. raised its holdings in shares of NxStage Medical by 1.1% in the 1st quarter. Principal Financial Group Inc. now owns 28,191 shares of the medical device company’s stock worth $757,000 after buying an additional 303 shares in the last quarter. Amalgamated Bank raised its holdings in shares of NxStage Medical by 7.1% in the 2nd quarter. Amalgamated Bank now owns 8,357 shares of the medical device company’s stock worth $210,000 after buying an additional 553 shares in the last quarter. Legal & General Group Plc raised its holdings in shares of NxStage Medical by 3.5% in the 2nd quarter. Legal & General Group Plc now owns 25,349 shares of the medical device company’s stock worth $630,000 after buying an additional 856 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its holdings in shares of NxStage Medical by 2.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 50,336 shares of the medical device company’s stock worth $1,262,000 after buying an additional 1,059 shares in the last quarter. 92.31% of the stock is owned by institutional investors and hedge funds.

NxStage Medical, Inc. (NASDAQ NXTM) opened at $25.80 on Tuesday. NxStage Medical, Inc. has a twelve month low of $20.45 and a twelve month high of $30.80.

A number of research firms recently weighed in on NXTM. William Blair cut NxStage Medical from an “outperform” rating to a “market perform” rating in a report on Monday, August 7th. Zacks Investment Research raised NxStage Medical from a “hold” rating to a “buy” rating and set a $33.00 price target for the company in a report on Thursday, August 10th. Leerink Swann cut NxStage Medical from an “outperform” rating to a “market perform” rating and raised their price target for the company from $28.00 to $30.00 in a report on Tuesday, August 22nd. Canaccord Genuity cut NxStage Medical from a “buy” rating to a “hold” rating and set a $30.00 price target for the company. in a report on Monday, August 7th. Finally, BidaskClub cut NxStage Medical from a “hold” rating to a “sell” rating in a report on Monday, July 31st. Two research analysts have rated the stock with a sell rating and eight have given a hold rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $30.25.

WARNING: “State of Wisconsin Investment Board Buys Shares of 485,600 NxStage Medical, Inc. (NXTM)” was posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this report can be accessed at https://www.chaffeybreeze.com/2017/11/14/state-of-wisconsin-investment-board-buys-shares-of-485600-nxstage-medical-inc-nxtm.html.

In other NxStage Medical news, President Joseph E. Turk, Jr. sold 1,000 shares of NxStage Medical stock in a transaction dated Wednesday, October 4th. The stock was sold at an average price of $27.56, for a total value of $27,560.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Matthew W. Towse sold 4,300 shares of NxStage Medical stock in a transaction dated Monday, August 21st. The shares were sold at an average price of $29.22, for a total value of $125,646.00. Following the completion of the sale, the senior vice president now directly owns 28,721 shares in the company, valued at approximately $839,227.62. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 14,100 shares of company stock worth $394,667. Corporate insiders own 4.70% of the company’s stock.

NxStage Medical Company Profile

NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.

Institutional Ownership by Quarter for NxStage Medical (NASDAQ:NXTM)

Receive News & Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply